Intravenous anti-platelet therapy—GP IIb/IIIa blockers and cangrelor

2020 ◽  
pp. 131-135
Author(s):  
Shraddha Ranjan ◽  
Gagandeep Singh Wander
Phlebologie ◽  
2008 ◽  
Vol 37 (06) ◽  
pp. 287-297 ◽  
Author(s):  
P.-M. Baier ◽  
Z. T. Miszczak

Summary Background: Platelet function inhibitors (PFI) are used for prophylaxis of atherothrombosis. These drugs cause a prolongation of the bleeding time and should eventually be stopped before an elective operation. However, there is a risk that a perioperative pause of PFI lead to acute atherothrombosis. Objective: Our aim was to study whether a discontinuation of PFI therapy is necessary to avoid bleeding complications in patients undergoing varicose vein surgery. Methods: Selective review of the literature and retrospective analysis of clinical data of our own patients. Results: In the years 2002 to 2007 a total of 10 827 patients have been operated on varicose veins, 673 (6.2%) of these aged 32–86 years (67 ± 7.9) receiving permanent PFI therapy: 256 male patients (38.0%) and 417 female (62.0%), 39.1% categorized as ASA III patients: male 11.6%, female 27.5%. 38 patients who continued PFI therapy did not demonstrate haemorrhagic complications and none of those pausing anti-platelet medication experienced thromboembolic complications. The literature survey confirmed our finding that it is not necessary to suspend PFI medication for varicose vein surgery as the bleeding risk can be controlled for by technical means. Conclusion: Discontinuation of PFI therapy prior to interventions on varicose veins does not seem to be necessary, further studies are essential though.


2013 ◽  
Vol 42 (5) ◽  
pp. 1418-1420 ◽  
Author(s):  
Irina Bobolea ◽  
Rosario Cabañas ◽  
Jesús Jurado-Palomo ◽  
Ana Fiandor ◽  
Santiago Quirce

2020 ◽  
pp. 79-87
Author(s):  
Kunal Mahajan ◽  
Yashasvi Rajeev ◽  
K Sarat Chandra

2017 ◽  
Vol 18 ◽  
pp. e112-e116 ◽  
Author(s):  
Pompilio Faggiano ◽  
Nicola Gaibazzi ◽  
Giacomo Faden ◽  
Federica Guidetti

2018 ◽  
Vol 11 (4) ◽  
pp. 1967-1974
Author(s):  
Praveen Panchaksharimath ◽  
A. N. Praveen ◽  
R. Manjunath

Drug utilization study is a powerful exploratory tool to evaluate the present trends of drug prescribing and appropriateness of prescription. To analyse the age and gender related differences in utilization of different classes of drugs in patients for Ischemic heart disease (IHD) management. This cross-sectional observational study was conducted from August 2017 to March 2018 in Cardiology department, PMSSY, BMC&RI, Bengaluru. The demographic, and drug prescription data of IHD patients were analyzed according to age group (18–59 years versus ≥ 60 years) and gender wise. Out of 520 patients diagnosed with IHD, 68% were male patients and 60% were aged ≥ 60 years. The most common co-morbid condition was Hypertension (66%) and was significant in patients aged ≥ 60 years (P= 0.0033). Anti-platelet drugs (100%) followed by Lipid lowering drugs (96%) were most commonly prescribed. The average number of drugs per prescription was found to be 6.44. Prescription of Dual anti-platelet therapy was found to be significant among men (<0.0001). Prescription of Diuretics (p = 0.045) and Pregabalin (p = 0.031) were significantly higher among females and Prescription of Angiotensin receptor blockers (ARBs) was significantly higher among those aged 18–59 years. Hypertension and Diabetes Mellitus were the most common co-morbidities observed with IHD. ARBs, Diuretics, Proton pump inhibitors, Anti Diabetic Agents and Pregabalin showed significant differences in the drug utilization with respect to age and gender. Dual anti-platelet therapy was observed to be significantly higher among males. This study has been registered in CTRI (CTRI/2018/05/013949).


Sign in / Sign up

Export Citation Format

Share Document